<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50182">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786629</url>
  </required_header>
  <id_info>
    <org_study_id>BLI800-480</org_study_id>
    <nct_id>NCT01786629</nct_id>
  </id_info>
  <brief_title>BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</brief_title>
  <official_title>BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety, tolerance and efficacy of SUPREP Bowel Prep Kit to an FDA approved
      control as bowel preparations prior to colonoscopy in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>% of subjects with successful preparation rated by blinded colonoscopist on a 4 point scale (1= poor to 4 = excellent)</measure>
    <time_frame>1 Day of colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Less than 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Bowel Preparation</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>SUPREP Bowel Prep Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUPREP Bowel Prep Kit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA approved bowel preparation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved bowel preparation containing electrolytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUPREP Bowel Prep Kit</intervention_name>
    <description>solution for oral administration prior to colonoscopy</description>
    <arm_group_label>SUPREP Bowel Prep Kit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved bowel preparation containing electrolytes</intervention_name>
    <description>solution for oral administration prior to colonoscopy</description>
    <arm_group_label>FDA approved bowel preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female outpatients who are undergoing colonoscopy for a routinely accepted
        indication.

        At least 18 years of age

        If female, and of child-bearing potential, is using an acceptable form of birth control

        Negative urine pregnancy test at screening, if applicable

        In the Investigator's judgment, subject is mentally competent to provide informed consent
        to participate in the study

        Exclusion Criteria:

        Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
        obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.

        Subjects who had previous significant gastrointestinal surgeries

        Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with
        clinically significant electrolyte abnormalities based on screening laboratory results,
        such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia,
        dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme
        (ACE) inhibitors.

        Subjects with a prior history of renal, liver or cardiac insufficiency

        Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

        Subjects undergoing colonoscopy for foreign body removal and/or decompression.

        Subjects who are pregnant or lactating, or intending to become pregnant during the study.

        Subjects of childbearing potential who refuse a pregnancy test.

        Subjects allergic to any preparation components.

        Subjects who, in the opinion of the Investigator, should not be included in the study for
        any reason, including inability to follow study procedures.

        Subjects who have participated in an investigational surgical, drug, or device study
        within the past 30 days.

        Subjects who withdraw consent before completion of Visit 1 procedures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island GI Research Group</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterology Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Gastroenterology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Sodium sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
